Astellas reports 22% sales bump for Izervay, expects trend to continue this year
10th July 2025 Uncategorised 0After reporting a 15% sequential decline in sales of Izervay in the opening quarter of this year, Astellas has reversed the momentum for its geographic atrophy (GA) treatment and is projecting the upward trend to continue this year. Analysts aren’t sold, however, on the company’s rosy expectations.
More: Astellas reports 22% sales bump for Izervay, expects trend to continue this year
Source: fierce